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We recently found a markedly lower prevalence of vascular
complications, including kidney disease, in diabetic patients
with Gilbert syndrome, a congenital form of
hyperbilirubinemia, suggesting a beneficial effect of bilirubin
(BIL) on diabetic nephropathy. To directly examine this, we
determined whether hereditary hyperbilirubinemic Gunn j/j
rats and biliverdin (BVD)-treated diabetic db/db mice were
resistant to the development of renal disease. Both rodent
models had less albuminuria and complete protection
against the progression of mesangial expansion
accompanied by normalization of transforming growth
factor-b1 and fibronectin expression. Simultaneously, there
was normalization of urinary and renal oxidative stress
markers, and the expression of nicotinamide adenine
dinucleotide phosphate (NAD(P)H) oxidase subunits in the
kidney. In cultured vascular endothelial and mesangial cells,
BIL and BVD significantly inhibited NADPH-dependent
superoxide production, and both high glucose- and
angiotensin II-induced production of reactive oxygen species.
Collectively, our findings suggest that BIL and BVD may
protect against diabetic nephropathy and may lead to novel
antioxidant therapies for diabetic nephropathy.
Kidney International (2010) 78, 905–919; doi:10.1038/ki.2010.265;
published online 4 August 2010
KEYWORDS: albuminuria; diabetic nephropathy; NADPH oxidase; oxidative
stress
Worldwide, diabetic nephropathy is a leading cause of end-
stage renal failure. Recent epidemiological studies have
revealed that diabetic nephropathy is also associated with
increased risk of cardiovascular events. A therapeutic
approach targeting its causative mechanisms urgently needs
to be established. In recent years, oxidative stress has been
considered to be an important pathogenic factor in the
development of diabetic vascular complications, including
nephropathy.1–4 Accumulating evidence has shown that many
protein, lipid, and DNA markers of oxidative stress are
increased in kidney and vascular tissues from animals and
patients with diabetes.3–5 However, trials using various
known antioxidants failed to protect against diabetic
nephropathy in humans.
Bilirubin (BIL) has been recognized as an endogenous
antioxidant for many years.6 Its formation is mediated by the
ubiquitously expressed heme oxygenase, the rate-limiting
enzyme involved in heme catabolism. Heme oxygenase
participates in heme breakdown to generate biliverdin
(BVD), free ferrous iron, and carbon monooxide. Subse-
quently, BVD is rapidly converted to BIL by BVD reductase.
Recently, increasing evidence has suggested that heme
oxygenase and its reaction product BIL may serve as
important endogenous agents with cytoprotective activity
against oxidative stress injury.7–9 The anti-oxidative action of
BIL has been attributed to its highly efficient radical-
scavenging effect,6 whereas recent reports have shown that
its hydrophobic tetrapyrrole structure may inhibit the activity
of nicotinamide adenine dinucleotide phosphate (NAD(P)H)
oxidase.10,11 Notably, we and other investigators have shown
that the activation of NAD(P)H oxidase may be a major
cause of increased oxidative stress in diabetic renal and
vascular tissues.12–15 Therefore, we speculated that BIL might
have a beneficial effect on diabetic nephropathy. In this
context, we recently reported a markedly lower prevalence of
nephropathy and other vascular complications in diabetic
patients with Gilbert syndrome, a congenital hyperbilirubi-
nemia, along with reduced markers of oxidative stress and
inflammation.16 However, this association study does not
necessarily implicate BIL as causative factor in the observed
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lower prevalence of diabetic nephropathy. Therefore, to test
this hypothesis and explore the underlying molecular
mechanisms, we investigated (1) whether hereditary hyper-
bilirubinemic Gunn rats are resistant to the progression of
nephropathy after the onset of diabetes, (2) whether
administration of BVD, the precursor of BIL, protects against
diabetic nephropathy in db/db mice, a rodent model of type
2 diabetes. The underlying molecular mechanisms were also
explored in these experimental animal models and in vitro
culture studies.
RESULTS
Hyperbilirubinemic Gunn rats
The characteristics of experimental rats at 0, 8, and 24 weeks
after onset of diabetes are shown in Table 1. The total BIL
levels remained constant after an age of 4 weeks in Gunn j/j
rats and Gunn j/þ rats. At 8 weeks after the onset of
diabetes, the total serum BIL levels were 0.15±0.02 and
0.18±0.04 mg/dl in diabetic and non-diabetic Gunn j/þ
rats, respectively, and 7.01±0.43 and 9.47±0.04 mg/dl in
diabetic and non-diabetic Gunn j/j rats, respectively (Table 1).
Such marked increments in serum BIL levels in Gunn j/j rats
reflect increases in the levels of unconjugated BIL.
Diabetic Gunn j/þ rats exhibited marked increases in the
amounts of urinary albumin excretion compared with non-
diabetic Gunn j/þ rats at 8 weeks (Po0.01) and 24 weeks
(Po0.001) after the onset of diabetes, whereas diabetic Gunn
j/j rats exhibited significantly less urinary albumin excretion
than diabetic Gunn j/þ rats at 8 weeks (Po0.05) and 24
weeks (Po0.001) (Figure 1).
To explore the mechanism underlying these beneficial
effects of hyperbilirubinemia, we measured systemic oxida-
tive stress markers, urinary 8-hydroxy-20-deoxyguanosine
(8-OHdG) excretion and 8-epi-prostaglandin F2a levels.
Urinary excretion levels of both 8-OHdG and
8-epi-prostaglandin F2a were significantly higher in diabetic
Gunn j/þ rats than in non-diabetic Gunn j/þ rats at
8 weeks. (Figure 2a and b). The diabetes-induced increases in
both oxidative markers at 8 weeks were completely prevented
in diabetic hyperbilirubinemic Gunn j/j rats, which showed
levels comparable to those in non-diabetic Gunn j/þ rats.
Immunostaining analysis of 8-OHdG in renal tissues
revealed that the staining intensities in diabetic Gunn j/þ
rats were significantly higher than those in control Gunn j/þ
rats, in both glomeruli and tubules at 24 weeks (Figure 2c–f).
These increases in 8-OHdG staining intensities in glomeruli
and tubules were completely prevented in diabetic Gunn j/j
rats, which showed levels comparable to those in control
Gunn j/þ rats (both non-significant vs control).
Furthermore, we examined the expression of renal
NAD(P)H oxidase components. To examine the localization
and expression levels of NOX4 protein, we carried out
immunostaining analysis. The staining intensities for NOX4
protein were stronger in the renal glomeruli and tubules of
diabetic Gunn j/þ rats than in those of control Gunn
j/þ rats (Figure 3a and b). Western blotting analysis
confirmed that the protein levels for NOX4 were significantly
increased in the kidneys of diabetic Gunn j/þ rats compared
with control Gunn j/þ rats (Po0.001; Figure 3c). All of
these changes were completely prevented in diabetic Gunn j/j
rats, which showed levels comparable to those in control
Gunn j/þ rats.
Table 1 | Body weights, blood glucose, and serum total/direct
bilirubin levels in Gunn j/+ and j/j rats at baseline, 8 weeks,
and 24 weeks after STZ-injection
j/+ j/+ j/j j/j
Control (n=10) DM (n=10) Control (n=10) DM (n=10)
Weight (g)
0 weeks 264.0±3.6 262.5±7.4 248.0±3.5 230.0±9.8
8 weeks 439.0±3.6 278.8±11.1a 400.0±5.9 219.3±16.6b
24 weeks 548.5±11.0 287.0±9.7a 444.4±6.8 225.0±19.4b
Blood glucose level (mg/dl)
0 weeks 123.6±2.1 123.9±6.9 123.1±3.7 117.8±9.6
8 weeks 107.9±3.3 550.9±28.4a 113.0±1.0 518.3±15.8b
24 weeks 188.9±12.2 556.3±11.1a 178.9±9.5 524.4±20.8b
Serum total bilirubin level (mg/dl)
8 weeks 0.18±0.04 0.15±0.02 9.47±0.04 7.01±0.43b
Serum direct bilirubin level (mg/dl)
8 weeks 0.06±0.01 0.07±0.03 0.64±0.03 0.51±0.03
Abbreviations: DM, streptozotocin-induced diabetic; STZ, streptozotocin.
Data are means±s.e.
ao0.001 vs j/+ control.
bo0.001 vs j/j control.
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Figure 1 |Ur Alb/Cr ratio in homozygous j/j (n=10) and
heterozygous j/+ Gunn rats (n=10) at 8 and 24 weeks after the
onset of diabetes. A 24-h urine sample was collected using
metabolic cages. The well-mixed urine was centrifuged at 7500 g
for 5min and then stored at 801C until analysis. Ur Alb/Cr ratio
(mg/g creatinine) was measured as described in the Materials and
Methods. Results are expressed as means±s.e. *Po0.05;
**Po0.01; ***Po0.001. Contr, non-diabetic; DM, streptozotocin-
induced diabetic; Ur Alb/Cr, urinary albumin/creatinine.
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Real-time PCR analysis showed that the mRNA levels for
NOX4 and other components, p22phox and p47phox, were also
significantly increased in the kidneys of diabetic Gunn j/þ rats
compared with control Gunn j/þ rats (Figure 3d–f). All of these
changes were completely prevented in diabetic Gunn j/j rats, which
showed levels comparable to those in control Gunn j/þ rats.
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Figure 2 |Urinary oxidative stress markers in homozygous j/j (n=10) and heterozygous j/+ (n=10) Gunn rats at 8 or 24 weeks after
the onset of diabetes. Urinary 8-hydroxy-20-deoxyguanosine (8-OhdG) excretion (mg/g creatinine) (a), and urinary 8-epi-prostaglandin
(8-epi-PG) F2a excretion (mg/g creatinine) (b) were measured as described in the Materials and Methods. Results are expressed as
means±s.e. *Po0.05; **Po0.01. Immunostaining analysis of renal 8-OHdG. Renal 8-OHdG contents were evaluated by immunostaining
analysis. The pictures are representative of the samples of glomeruli (c) and tubules (d) from non-diabetic heterozygous Gunn j/þ rats
(n¼ 10), diabetic heterozygous Gunn j/þ rats (n¼ 10), non-diabetic homozygous Gunn j/j rats (n¼ 10), and diabetic homozygous Gunn j/j
rats (n¼ 10). The immunostaining intensities of 8-OHdG in the renal glomeruli (e) and tubules (f) were semi-quantitatively evaluated using
Scion imaging software (Scion, Frederick, MD, USA). Results are expressed as the mean percentages of the levels in non-diabetic
heterozygous Gunn j/þ rats±s.e. ***Po0.001. Contr, non-diabetic; DM, streptozotocin-induced diabetic.
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We investigated the effect of hyperbilirubinemia on
mesangial expansion at 24 weeks after the onset of diabetes.
The glomerular structure in diabetic Gunn j/þ rats showed
accelerated mesangial expansion compared with that ob-
served in control Gunn j/þ rats (Figure 4a). The periodic
acid-Schiff-positive and nuclei-free mesangial area was
markedly increased in the glomeruli of diabetic Gunn j/þ
rats (Po0.001; Figure 4b). Diabetic Gunn j/j rats showed
complete prevention of mesangial expansion.
We also examined the effect of hyperbilirubinemia on the
levels of transforming growth factor-b1 (TGF-b1) and fibro-
nectin. The levels of TGF-b1/fibronectin mRNA and protein
were significantly increased in the kidneys of diabetic Gunn
j/þ rats compared with control Gunn j/þ rats (Figure 4c–f).
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Figure 3 | Immunostaining analysis of NOX4 protein levels in renal tissues. The pictures are representative of the samples of glomeruli
(a) and tubules (b). Similar results were obtained in all samples from the kidneys of each group (n¼ 10). NOX4 protein levels were evaluated
by western blot analysis. Pictures are representative of western blots for NOX4 in renal tissues (c). NOX4 levels were normalized to the level
of b-actin and the results are expressed as the mean percentages of the levels in control heterozygous Gunn j/þ rats±s.e. (For all groups,
n¼ 10.) ***Po0.001. The levels of mRNA for NOX4, p22phox, and p47phox in renal tissues. Total RNA was extracted from the kidneys of
each group (n¼ 10) of rats at 24 weeks after the onset of diabetes. NOX4, p22phox, and p47phox mRNA levels were measured by real-time
reverse transcriptase PCR (d–f). The levels of mRNA were normalized to the levels of b-actin and the results are expressed as the mean
percentages of the levels in control heterozygous Gunn j/þ rats±s.e. *Po0.05; **Po0.01. Contr, non-diabetic; DM, streptozotocin-induced
diabetic.
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In diabetic Gunn j/j rats, the increases in TGF-b1 and
fibronectin levels were significantly prevented.
BVD administration
Next, we investigated the effect of BVD administration on
albuminuria, oxidative stress, and renal mesangial expansion
in db/db mice.
BVD administration (5 mg/kg) orally for 2 weeks and 12
weeks did not significantly affect body weights or blood
glucose levels (Table 2). Oral administration of this dose of
BVD did not induce a significant elevation in serum BIL
levels (Table 2), although an intraperitoneal injection of the
same dose induced a slight elevation in serum BIL levels at
0.5 h, with rapid return to the basal levels at 6 h after injection
(data not shown).
Urinary albumin excretion significantly increased in non-
treated db/db mice as compared with control db/þ mice at
2 weeks and 12 weeks after the start of BVD administration
(Figure 5). BVD administration significantly attenuated such
increases in urinary albumin excretion in db/db mice.
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Figure 4 |Mesangial expansion in homozygous j/j and heterozygous j/+ Gunn rats (a, b). At 24 weeks after the onset of diabetes, renal
sections were stained with periodic acid-Schiff. The pictures are representative of samples from non-diabetic heterozygous Gunn
j/þ rats (n¼ 10), non-diabetic homozygous Gunn j/j rats (n¼ 10), diabetic heterozygous Gunn j/þ rats (n¼ 10), and diabetic homozygous
Gunn j/j rats (n¼ 10). Semi-quantitative analysis of the mesangial area. Results are expressed as the mean percentages of the areas in non-
diabetic heterozygous Gunn j/þ rats±s.e. ***Po0.001. Transforming growth factor-b1 (TGF-b1) and fibronectin mRNA and protein levels
(c–f). Total RNA and protein were extracted from the kidneys of each group of rats 24 weeks after the onset of diabetes (for all groups,
n¼ 10). TGF-b1 and fibronectin mRNA levels were measured by real-time reverse transcriptase PCR (c, d). The levels of mRNA were
normalized to the levels of b-actin and the results are expressed as the mean percentages of the levels in control heterozygous Gunn
j/þ rats±s.e. TGF-b1 and fibronectin protein levels were evaluated by western blot analysis (e, f). Pictures are representative of western
blots of TGF-b1 and fibronectin in the renal tissues. The levels of protein were normalized to the levels of b-actin and the results
are expressed as the mean percentages of the levels in control heterozygous Gunn j/þ rats±s.e. *Po0.05; **Po0.01; ***Po0.001.
Contr, non-diabetic; DM, streptozotocin-induced diabetic.
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8-OHdG in renal tissues) was significantly higher in db/db
mice than in control db/þ mice. BVD administration
completely normalized these markers in db/db mice to
control levels (Figure 6a–f). We also confirmed the effect of
BVD to intracellular production of superoxide in the renal
tissues by dihydroethidium (DHE) stain. The oxidized DHE
signals were significantly higher in db/db mice than those in
control mice at 12 weeks (Figure 6g–j). BVD administration
completely normalized the oxidized DHE signals to the
control levels. Then, we evaluated the NADPH oxidase
activities, using the lucigenin-enhanced chemiluminescence
method as previously described.17 BVD administration
significantly suppressed diabetes-induced activation of
NADPH oxidase in crude cortex homogenates up to control
levels (Figure 6k).
Furthermore, to examine the levels of NOX4 protein, we
carried out immunostaining analysis and western blot
analysis. The protein levels of NOX4 were also significantly
increased in renal tissues of db/db mice. BVD administration
completely normalized all of these changes in db/db mice to
the control levels (Figure 7a–c).
The levels of mRNA for NOX4 and other components,
p22phox and p47phox, were also significantly increased in
the kidney of db/db mice as compared with control mice
(Po0.05; Po0.05; Po0.05; Figure 7d–f). Likewise, the levels
of mRNA for NAD(P)H oxidase components in glomeruli
were significantly increased in db/db mice as compared
with control mice(Po0.01; Po0.01; Po0.01; Figure 7g–i).
These abnormalities were completely normalized by BVD
administration. We evaluated the levels of mRNA for heme
Table 2 | Body weights, blood glucose, and serum total/direct
bilirubin levels in db/+ and db/db mice at baseline, 2 weeks,
and 12 weeks after treatment.
db/+ db/db db/+ db/db
(n=8) (n=8) +BVD (n=8) +BVD (n=8)
Weight (g)
0 weeks 28.4±0.4 50.2±0.5a 29.9±0.7 51.4±0.6b
2 weeks 29.7±0.4 51.5±0.5a 29.8±0.5 51.6±0.4b
12 weeks 32.1±0.7 53.9±1.1a 33.0±0.7 52.9±0.6b
Blood glucose level (mg/dl)
0 weeks 124.6±4.8 474.6±20.5a 131.3±6.1 483.0±11.2b
2 weeks 145.8±3.5 545.9±16.6a 121.3±8.4 530.1±22.7b
12 weeks 154.2±4.4 574.6±13.2a 145.8±3.5 522.4±43.5b
Serum total bilirubin level (mg/dl)
0 weeks 0.74±0.08 0.70±0.05 0.74±0.07 0.76±0.06
2 weeks 0.98±0.03 0.99±0.04 0.95±0.03 0.98±0.03
Serum direct bilirubin level (mg/dl)
0 weeks 0.26±0.05 0.24±0.03 0.25±0.02 0.26±0.02
2 weeks 0.22±0.02 0.20±0.02 0.21±0.03 0.21±0.02
Abbreviation: BVD, biliverdin.
Data are means±s.e.
ao0.01 vs non-treated db/+.
bo 0.01 vs treated db/+.
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Figure 5 | Effect of biliverdin (BVD) treatment on Ur Alb/Cr
ratio in db/+ mice (n¼ 8) and db/db mice (n¼ 8). BVD
(5mg/kg) was administered to db/db and db/þ mice starting at
12 weeks of age for 2 or 12 weeks. A 24-h urine sample was collected
using metabolic cages. The well-mixed urine was centrifuged at
7500g for 5min and then stored at 801C until analysis. Ur Alb/Cr
ratio (mg/g creatinine) was measured as described in the Materials
and Methods. *Po0.05, **Po0.01, ***Po0.001. BVD, BVD treated
mice; Ur Alb/Cr, urinary albumin/creatinine.
Figure 6 | The effect of biliverdin (BVD) treatment on urinary 8-hydroxy-20-deoxyguanosine (8-OhdG) excretion and urinary
8-epi-prostaglandin (8-epi-PG) F2a excretion. Urinary 8-OHdG excretion (mg/g creatinine) (a), and urinary 8-epi-PG F2a excretion
(mg/g creatinine) (b) were measured after 2 and 12 weeks treatment, as described in the Materials and Methods. Results are expressed as
means±s.e. (For all groups, n¼ 8.) *Po0.05, **Po0.01, ***Po0.001. Immunostaining analysis of renal 8-OHdG. The pictures are
representative of the samples of glomeruli (c) and tubules (d) from non-treated db/þ mice (n¼ 8), non-treated db/db mice (n¼ 8),
BVD-treated db/þ mice (n¼ 8), and BVD-treated db/db mice (n¼ 8). The immunostaining intensities of 8-OHdG in the renal glomeruli and
tubules were semi-quantitatively evaluated using Scion imaging software (Scion) (e, f). Results are expressed as the mean percentages of
the levels in non-treated db/þ mice±s.e. *Po0.05; ***Po0.001. The effect of BVD treatment on ROS production was detected by
dihydroethidium (DHE) stain in the renal tissues. The pictures are representative of the samples of glomeruli (g) and tubules (h) from
non-treated db/þ mice (n¼ 8), non-treated db/db mice (n¼ 8), BVD-treated db/þ mice (n¼ 8), and BVD-treated db/db mice (n¼ 8). The
emission intensities of DHE oxidation in the renal glomeruli and tubules were semi-quantitatively evaluated using Scion imaging software
(Scion) (i, j). Results are expressed as the mean percentages of the levels in non-treated db/þ mice±s.e. ***Po0.001. Nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity assay for crude cortex homogenates from non-treated db/þ mice (n¼ 8),
non-treated db/db mice (n¼ 8), BVD-treated db/þ mice (n¼ 8), and BVD-treated db/db mice (n¼ 8) (k). After establishing a background
rate for 5min, NADPH was added and the increase in lucigenin-enhanced chemiluminesence was monitored by Flex Station 3, Molecular
Devices, Tokyo, Japan. Results are expressed as means±s.e. *Po0.05, **Po0.01 vs db/db mice.
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oxygenase-1 in all these groups, but there was no significant
change among them.
Mesangial expansion was found in db/db mice at the age
of 24 weeks (Po0.001; Figure 8a and b), with increased
mRNA and protein levels of TGF-b1 (Figure 8c and e) and
fibronectin (Figure 8d and f) in the kidney of db/db mice, as
well as in glomeruli (Figure 8g and h). These abnormalities
were completely prevented by BVD administration.
In vitro effect of BIL and BVD on NAD(P)H oxidase activities
The effect of BIL and BVD on NAD(P)H oxidase activities in
cultured human mesangial cells were evaluated by the
lucigenin method. Pre-treatment of the cells with both BIL
and BVD for 48 h reduced NAD(P)H oxidase activities in a
dose-dependent manner (Figure 9a and b). In addition,
intracellular oxidative stress was evaluated by the 20,70-
dichlorofluorescein diacetate staining method as previously
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Figure 7 | The effect of biliverdin (BVD) treatment on NOX4 protein levels in renal tissues. Immunostaining analysis of NOX4
protein levels in renal tissues. The pictures are representative of the samples of glomeruli and tubules (a, b). Similar results were obtained
in all samples from the kidneys of each group. (For all groups, n¼ 8.) NOX4 protein levels were evaluated by western blot analysis (c).
The levels of protein were normalized to the level of b-actin and the results are expressed as the mean percentages of the levels in
non-treated db/þ mice±s.e. (For all groups, n¼ 8.) **Po0.01. The expression of mRNA levels for the NOX4, p22phox, and p47phox in renal
tissues. Total RNA was extracted from the kidneys after 12 weeks of BVD treatment and the levels of mRNA were measured by real-time
reverse transcriptase PCR (RT-PCR) (d–f). The levels of mRNA were normalized to the levels of b-actin and the results are expressed as the
mean percentages of the levels in non-treated db/þ mice±s.e. (For all groups, n¼ 8.) *Po0.05; ***Po0.001. The expression of mRNA
levels for NOX4, p22phox, and p47phox in the glomeruli. Total RNA was extracted from the glomeruli after 12 weeks of BVD treatment. The
each extracted mRNA level from the glomeruli was measured by real-time RT-PCR (g–i). The levels of mRNA were normalized to the levels
of b-actin and the results are expressed as the mean percentages of the levels in non-treated db/þ mice±s.e. (For all groups, n¼ 8.) **Po0.01.
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described.18 20,70-Dichlorofluorescein diacetate staining
showed that exposure of the cells to angiotensin II (Ang II;
100 nmol/l) for 4 h and high glucose levels (450 mg/dl)
for 24 h increased intracellular oxidative stress as compared
with the control levels (Figure 9c and d). These increases
in intracellular oxidative stress were completely norma-
lized to the control levels by treatment with BIL for 1 h
(10 mmol/l).
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Finally, we investigated the effect of BIL and BVD on the
expression of NOX4, TGF-b1, and fibronectin in cultured
human mesangial cells. Ang II stimulated the expression
levels of NOX4 mRNA in a time-dependent manner
(Figure 10a). Treatment with BIL and BVD completely
inhibited the increased expression of NOX4 mRNA, whereas
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N-acetylcysteine and a-lipoic acid did not, even at the
maximal concentration. The protein levels of NOX4 were also
inhibited by BIL and BVD (Figure 10b). We confirmed that
the increased expression of mRNAs of TGF-b1 and
fibronectin induced by Ang II was also completely prevented
by BIL and BVD in all time courses, whereas N-acetylcysteine
and a-lipoic acid did not (Figure 10c and d).
DISCUSSION
In this study, to reveal the protective effect of BIL on diabetic
nephropathy, we first used streptozotocin-induced diabetic
homozygous Gunn rats, which exhibit a marked elevation of
plasma unconjugated BIL levels owing to a genetic deficiency
of uridine diphosphate glucuronosyl transferase-1. The
present study showed that diabetic hyperbilirubinemic Gunn
j/j rats exhibited significantly less urinary albumin excretion
than diabetic non-hyperbilirubinemic Gunn j/þ rats. In
addition, diabetic Gunn j/j rats did not develop renal
mesangial expansion, which is one of the most striking
morphological features of diabetic nephropathy, 6 months
after the onset of diabetes, whereas diabetic Gunn j/þ rats
developed typical mesangial expansion. TGF-b is a key
cytokine that mediates the changes, which leads to extra-
cellular matrix accumulation and glomerular expansion in
diabetes.19 We also found that the increased expression of
TGF-b and fibronectin, a major matrix protein, was
prevented in diabetic Gunn j/j rats. These findings suggested
that hyperbilirubinemic Gunn j/j rats were resistant to the
progression of functional and morphological features of
nephropathy after the onset of diabetes. Second, we used
db/db mice, a rodent model of type 2 diabetes to evaluate
the effect of administration of BVD, a precursor of BIL.
We administered BVD (5 mg/kg) orally instead of BIL,
because BVD is relatively more water-soluble than BIL. Oral
administration of this dose of BVD did not induce a
significant elevation in serum BIL levels. Nevertheless, the
present study showed that administration of BVD (5 mg/kg)
protected against both albuminuria and renal mesangial
expansion in db/db mice. As serum BVD enters cells rapidly
and is converted to BIL by BVD reductase,20 it is likely that
the beneficial effect of BVD administration may be because of
increased levels of intracellular BIL levels generated from
exogenously administered BVD, rather than increased levels
of serum BIL or BVD.
The present study further suggested that the mechanism
underlying these beneficial effects of hyperbilirubinemia and
BVD administration may be the inhibition of oxidative stress,
evaluated by systemic oxidative stress markers (urinary
excretion of 8-OHdG and 8-epi-prostaglandin F2a), 8-OHdG
staining, and DHE oxidation levels, which are relatively
superoxide-sensitive in renal tissues. As BIL has been
recognized to possess radical-scavenging activity,6 the
inhibition of oxidative stress may be, at least in part, owing
to its radical-scavenging activity. Notably, the serum BIL
levels in diabetic Gunn j/j rats were slightly, but significantly,
lower than those in non-diabetic Gunn j/j rats. Such a
decrease in serum BIL levels induced by diabetes may be a
reflection of its consumption owing to its radical-scavenging
activity, although this speculation should be confirmed in
future studies.
However more importantly, we revealed for the first time
that BVD administration induced downregulation of
NAD(P)H oxidase components (NOX4, p22phox, p47phox)
in diabetic kidneys, glomeruli, and human mesangium cells.
Although the nature of the sources of reactive oxygen species
(ROS) overproduction in diabetes has not been precisely
defined, we and other investigators have indicated that non-
phagocytic NAD(P)H oxidases may be the major sources of
increased ROS production in the vascular tissues of diabetic
animals and patients.12,13,15 The non-phagocytic NAD(P)H
oxidase comprises of a membrane-associated cytochrome
b558 composed of NOX family proteins (gp91phox, NOX1,
NOX4) and p22phox, and several cytosolic regulatory
components, p47phox, p67phox, and Rac 1 or Rac 2.21 The
isoform NOX4 was cloned from the kidney, where it was
found to be highly expressed.22,23 It has been suggested that
NOX4, as a major source of ROS production in the kidney,
could have a role under pathological conditions. We
previously reported that increased expression of NOX4 may
have an important role in increased ROS production in the
kidneys of streptozotocin-induced diabetic rats.24–26 Gorin
et al.27 confirmed the increased expression of NOX4 in the
diabetic kidney, and further revealed that downregulation of
NOX4 induced by antisense oligonucleotides completely
Figure 8 | The effect of biliverdin (BVD) treatment on mesangial expansion (a, b). After 12 weeks of treatment, renal sections were
stained with periodic acid-Schiff. The pictures are representative of samples from non-treated db/þ mice (n¼ 8), non-treated db/db mice
(n¼ 8), BVD-treated db/þmice (n¼ 8), and BVD-treated db/db mice (n¼ 8). Semi-quantitative analysis of the mesangial area. Results are
expressed as the mean percentages of the areas in non-treated db/þ mice±s.e. ***Po0.001. Transforming growth factor-b1 (TGF-b1) and
fibronectin mRNA and protein levels (c–f). Total RNA and protein were extracted from the kidneys of each group of mice after 12 weeks BVD
treatment (for all groups, n¼ 8). TGF-b1 and fibronectin mRNA levels were measured by real-time reverse transcriptase PCR (RT-PCR)
(c, d). The levels of mRNA were normalized to the levels of b-actin and the results are expressed as the mean percentages of the levels in
non-treated db/þ mice±s.e. TGF-b1 and fibronectin protein levels were evaluated by western blot analysis (e, f). Pictures are
representative of western blots of TGF-b1 and fibronectin in the renal tissues. The levels of protein were normalized to the levels of b-actin
and the results are expressed as the mean percentages of the levels in non-treated db/þ mice±s.e. *Po0.05; **Po0.01; ***Po0.001. The
expression of mRNA levels for the TGF-b1 and fibronectin in the glomeruli. The extracted mRNA from the glomeruli were measured by real-
time RT-PCR (g, h). The levels of mRNA were normalized to the levels of b-actin and the results are expressed as the mean percentages of
the levels in non-treated db/þ mice±s.e. *Po0.05; **Po0.01.
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attenuated oxidative stress in the kidneys of streptozotocin-
induced diabetic rats. Taken together, the present results
suggest that downregulation of NAD(P)H oxidase compo-
nents, especially NOX4, by hyperbilirubinemia and BVD
administration may have an important role in the inhibition
of oxidative stress in the kidneys of diabetic rodents. We also
confirmed the inhibitory effect of hyperbilirubinemia and
BVD on NAD(P)H oxidase activities by the lucigenin
method.
The signaling mechanisms underlying the rapid activation
of non-phagocytic NAD(P)H oxidase in vascular cells have
been relatively well established. One of the most important
physiological regulators is Ang II.28 Ang II rapidly activates
phospholipase C to increase intracellular calcium and
diacylglycerol levels, which cause the activation of protein
kinase C. Activated protein kinase C phosphorylates p47phox
and induces the release of superoxide from NOX compo-
nents. We and other investigators have also reported that
high glucose levels stimulate superoxide production from
vascular endothelial cells and smooth muscle cells via a
protein kinase C-dependent activation of NAD(P)H oxi-
dase.12–15 In the diabetic state, high glucose levels and
activation of local renin-angiotensin systems may induce the
rapid activation of NAD(P)H oxidase in renal and vascular
tissues of diabetic patients and animals.29,30 A previous
report showed that the hydrophobic tetrapyrrole structure of
BIL can inhibit NAD(P)H oxidase activity directly in a cell-
free system,10 probably via inhibition of the interactions
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between regulatory components and NOX family members.
In the present study, we showed that BIL and BVD inhibited
NAD(P)H activities in cultured renal mesangial cells, and
inhibited high glucose-induced and Ang II-induced ROS
production. The inhibitory effect of BIL and BVD on the
expression of NAD(P)H oxidase components were also
confirmed. All these findings suggest that BIL and BVD
may inhibit oxidative stress in diabetic kidneys by their
inhibitory effects on both the activation and the over-
expression of NAD(P)H oxidase. Furthermore, the present
study revealed that BIL and BVD were more effective in
preventing Ang II-induced expression of NAD(P)H oxidase,
TGFb, and fibronectin in cultured mesangial cells than
maximal doses of other antioxidants such as N-acetylcysteine
and a-lipoic acid, supporting the effectiveness of BIL and
BVD on diabetic nephropathy. The detailed molecular
mechanisms for the beneficial effects of BIL and BVD should
be clarified in future studies.
Accumulating evidence has shown that subjects with
higher BIL levels have a lower incidence of cardiovascular
disease and strokes.31–33 Recently, we showed a markedly
lower prevalence of nephropathy as well as cardiovascular
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disease in diabetic patients with Gilbert syndrome.16 One
report has also shown that serum BIL level is associated with
microalbuminuria in patients with type 2 diabetes.34 These
epidemiological findings showing the relationship between
serum BIL level and prevalence of diabetic nephropathy are
consistent with the present findings implicating that
hyperbilirubinemia and BVD administration protect against
diabetic nephropathy.
In conclusion, we showed for the first time that
hyperbilirubinemia and BVD administration protected
against diabetic nephropathy via inhibition of oxidative
stress, at least in part by downregulating renal NAD(P)H
oxidase, in animal models of diabetes. The present findings
may lead to novel antioxidant therapies for early stages of
diabetic nephropathy.
MATERIALS AND METHODS
Animals
Male homologous Gunn j/j rats and age-matched heterozygous
Gunn j/þ rats were purchased from Clea Japan, Tokyo, Japan. At
8 weeks of age, half of the Gunn j/j rats (n¼ 10) and half of the
Gunn j/þ rats (n¼ 10) were injected intraperitoneally with
streptozotocin (Sigma, St Louis, MO, USA) at 80 mg/kg body
weight. At 1 or 2 days after injection, the development of diabetes
was verified by the presence of hyperglycemia (plasma glucose levels
416.7 mmol). Male C57BL/KsJ db/db mice and their age-matched
lean littermates, db/þ mice, were purchased from Clea Japan. All
mice were bred under pathogen-free conditions at Kyushu
University Animal Center, Fukuoka, Japan. The animals had free
access to tap water and standard chow (Clea Japan). At 12 weeks of
age, half of the db/db (n¼ 8) and half of the db/þ (n¼ 8) mice
were randomly chosen to receive powder diet (Clea Japan)
supplemented with BVD (5 mg/kg; Frontier Scientific, Logan, UT,
USA) and the rest of the mice received powder diet without any
supplementation for 2 or 12weeks. Powder diet was stored at 41C
and kept away from excessive light. All protocols were reviewed and
approved by the Ethics Committee of Animal Experiments,
Graduate School of Medical Science, Kyushu University.
Human mesangium cells and culture
Normal human mesangium cells were obtained from Lonza
(Walkersville, MD, USA) and cultured in BulletKit containing 5%
fetal bovine serum, 50 mg/ml gentamicin, and 50 mg/ml amphoter-
icin-B in a humidified air/5% CO2 atmosphere at 371C. All cells
were studied at passage 4. For more details, see online Supplement.
Blood and urine analysis
Plasma concentrations of total and direct BIL were measured and a
24-h urine sample was collected using metabolic cages to analyze
urinary albumin and oxidative stress makers. The well-mixed urine
was centrifuged at 7500 g for 5 min, purged of air with a steam of
nitrogen to prevent artificial formation of oxidative stress products,
and then stored at 801C until analysis. Relating to these analyses,
see online Supplement for details.
Immunohistochemistry
Immunostaining for 8-OHdG and NOX4 in the kidney was
performed as previously described.24 Methods are described in the
online appendix section.
DHE stain in the renal tissues
To detect ROS in the renal glomeruli and tubules, DHE (Invitrogen,
Carlsbad, CA, USA) stain was performed as previously described35
with a slightly modified procedure. The detailed method is
summarized in the online appendix section.
Isolaion of glomeruli
Isolation of mice glomeruli was performed using Dynabeads M-450
tosylactivated and Magnetic Particle Concentrator (Dynal AS, Oslo,
Norway) as previously described.36 We performed a slightly
modified procedure. The detailed method is summarized in the
online appendix section.
RNA extraction and quantitative reverse transcriptase-PCR
Methods are described in the online appendix section.
Morphological study
The mesangial matrix was determined by the presence of periodic
acid-Schiff-positive and nuclei-free areas. The detailed method is
summarized in the online appendix section.
Western blot analysis
Methods are described in the online appendix section.
Measurement of NAD(P)H oxidase activities
NAD(P)H oxidase activities in renal cortex tissues and mesangial
cell homogenates were evaluated by the lucigenin-enhanced
chemiluminescence method. Intracellular oxidative stress was
evaluated by the 20,70-dichlorofluorescein diacetate staining method.
Both detailed methods are summarized in the online appendix
section.
Statistical analysis
All data are expressed as means±s.e.m. Statistical analysis was
performed with Student’s t-test or one-way analysis of variance with
Fisher’s protected least significant difference test. Po0.05 was
considered statistically significant.
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